Award
National Institute of Arthritis and Musculoskeletal and Skin Diseases 5R41AR083738-02
Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis
Recipient
PROVIZIGEN LLC
Award Amount
$158,663.00
Ceiling
$158,663.00
Awarded
August 05, 2025
Identifier
5R41AR083738-02
NIH awarded a Phase I STTR contract to PROVIZIGEN LLC to develop and test a therapeutic hydrogel system for post-traumatic osteoarthritis treatment.
Description
The project involves developing a therapeutic hydrogel system, HydroGEN, for PTOA. The project aims to determine stability, toxicity, and biodistribution of HydroGEN. The project is funded by NIH, with a focus on translational research. The award is part of a Phase I STTR program leading to potential human trials.